 |
With the zeal to do something new and an entrepreneurial spirit, Kamath has led the company to a global leader position in a pharma intermediates segment, Isoxazole side-chains.
Generating revenues of USD 200 million, the company is supported by 2,400 customer-centric archers, 11 certified facilities, including cGMP-compliant, US FDA- and EDQM-approved sites, and two state-of-the-art process technology centres. The company’s customers range from emerging or specialty companies to global majors, many of whom have designated Arch Pharmalabs as a preferred supplier or strategic partner. The company received CNBC TV Emerging India 2006 Award as the No.1 small or medium company in the pharmaceuticals and chemicals category.
Backed by marquee investors, ICICI Ventures, Swisstec Ventures and Infrastructure Leasing & Financial Services Ltd, who collectively own 58 percent of the company, Arch Pharma is transforming the way chemistry and manufacturing are outsourced. The company’s team of 1,100 employees is working diligently to produce success for their customers and partners across the world.
| < Prev | Next > |
|---|
